Subscribe
Webinars
White Papers
Buyer's Guide
PhotonicsNXT
Get Published!
Lasers/Sources
Detectors/Imaging
Optics
Bio & Life Sciences
Laser Processing
Test/Measurement
Science & Research
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
BioOptics Stock Watch
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Moderna, Inc.
< Previous
1
2
3
4
5
Next >
Moderna to Present at Upcoming Investor Conferences in November 2021
October 28, 2021
From
Moderna, Inc.
Via
Business Wire
Tickers
MRNA
Moderna Named a Top Employer by Science for Seventh Consecutive Year
October 28, 2021
From
Moderna, Inc.
Via
Business Wire
Tickers
MRNA
Moderna Announces First Participant Dosed in Phase 3 Pivotal Registration Study of Its mRNA Cytomegalovirus (CMV) Vaccine
October 26, 2021
From
Moderna, Inc.
Via
Business Wire
Tickers
MRNA
Moderna Announces Swissmedic Authorizes Booster Dose of Moderna’s COVID-19 Vaccine
October 26, 2021
From
Moderna, Inc.
Via
Business Wire
Tickers
MRNA
Moderna Announces Memorandum of Understanding to Supply up to 110 Million Doses of Its COVID-19 Vaccine to the African Union
October 26, 2021
From
Moderna, Inc.
Via
Business Wire
Tickers
MRNA
Moderna Announces European Medicines Agency’s Committee for Medicinal Products for Human Use Recommends Booster Dose of Moderna’s COVID-19 Vaccine in the European Union
October 25, 2021
From
Moderna, Inc.
Via
Business Wire
Tickers
MRNA
Moderna Announces Positive Top Line Data from Phase 2/3 Study of COVID-19 Vaccine in Children 6 to 11 Years of Age
October 25, 2021
From
Moderna, Inc.
Via
Business Wire
Tickers
MRNA
U.S. CDC Advisory Committee on Immunization Practices Recommends Booster Vaccination with Moderna’s COVID-19 Vaccine
October 21, 2021
From
Moderna, Inc.
Via
Business Wire
Tickers
MRNA
Moderna Announces FDA Authorization of a Booster Dose of Moderna’s COVID-19 Vaccine in the U.S.
October 20, 2021
From
Moderna, Inc.
Via
Business Wire
Tickers
MRNA
Moderna Announces FDA Advisory Committee Unanimously Votes in Support of Emergency Use for a Booster Dose of Moderna’s COVID-19 Vaccine in the U.S.
October 14, 2021
From
Moderna, Inc.
Via
Business Wire
Tickers
MRNA
Moderna to Report Third Quarter Financial Results on Thursday, November 4, 2021
October 14, 2021
From
Moderna, Inc.
Via
Business Wire
Tickers
MRNA
Moderna Announces COVAX Exercises Option to Purchase 176.5 Million Additional Doses of Moderna’s COVID-19 Vaccine for Low Income Countries in First Half of 2022
October 12, 2021
From
Moderna, Inc.
Via
Business Wire
Tickers
MRNA
Moderna to Build State-of-the-Art mRNA Facility in Africa to Manufacture up to 500 Million Doses Per Year
October 07, 2021
From
Moderna, Inc.
Via
Business Wire
Tickers
MRNA
Moderna Announces the Launch of Global Fellowship Program for Young Researchers Exploring mRNA Medicines
October 06, 2021
From
Moderna, Inc.
Via
Business Wire
Tickers
MRNA
Moderna Announces European Medicines Agency Authorizes Third Dose of COVID-19 Vaccine for Immunocompromised Individuals Aged 12 Years and Older
October 05, 2021
From
Moderna, Inc.
Via
Business Wire
Tickers
MRNA
Moderna to Invest in New Science Center in Cambridge, MA
September 30, 2021
From
Moderna, Inc.
Via
Business Wire
Tickers
MRNA
Moderna to Present at Chardan’s Virtual 5th Annual Genetic Medicines Conference
September 28, 2021
From
Moderna, Inc.
Via
Business Wire
Tickers
MRNA
Moderna Announces Supply Agreement with Peru for 20 Million Doses of Its COVID-19 Vaccine
September 24, 2021
From
Moderna, Inc.
Via
Business Wire
Tickers
MRNA
Moderna Announces Health Canada Approves its COVID-19 Vaccine
September 16, 2021
From
Moderna, Inc.
Via
Business Wire
Tickers
MRNA
Moderna Highlights New Clinical Data on its COVID-19 Vaccine
September 15, 2021
From
Moderna, Inc.
Via
Business Wire
Tickers
MRNA
Moderna Announces Significant Advances Across Industry-Leading mRNA Portfolio at 2021 R&D Day
September 09, 2021
From
Moderna, Inc.
Via
Business Wire
Tickers
MRNA
Resilience to Manufacture mRNA for Moderna’s COVID-19 Vaccine
September 08, 2021
From
Moderna, Inc.
Via
Business Wire
Tickers
MRNA
Moderna and the Institute for Life Changing Medicines Announce a New Collaboration to Develop an mRNA Therapeutic for Ultra-Rare Disease, Crigler-Najjar Syndrome Type 1
September 07, 2021
From
Moderna, Inc.
Via
Business Wire
Tickers
MRNA
Moderna Announces Submission of Data to European Medicines Agency for its COVID-19 Vaccine Booster
September 03, 2021
From
Moderna, Inc.
Via
Business Wire
Tickers
MRNA
Moderna to Present at Upcoming Investor Conferences in September 2021
September 02, 2021
From
Moderna, Inc.
Via
Business Wire
Tickers
MRNA
Moderna Announces Submission of Initial Data to U.S. FDA for Its COVID-19 Vaccine Booster
September 01, 2021
From
Moderna, Inc.
Via
Business Wire
Tickers
MRNA
Moderna Completes Submission of Biologics License Application to the U.S. Food and Drug Administration for its COVID-19 Vaccine
August 25, 2021
From
Moderna, Inc.
Via
Business Wire
Tickers
MRNA
Moderna to Host Virtual R&D Day on Thursday, September 9, 2021
August 24, 2021
From
Moderna, Inc.
Via
Business Wire
Tickers
MRNA
Moderna Announces Supply Agreement with Canada for Expanded Supply of Moderna’s COVID-19 Vaccine in 2022, in 2023 and in 2024
August 16, 2021
From
Moderna, Inc.
Via
Business Wire
Tickers
MRNA
Moderna Announces First Patient Dosed in Phase 1/2 Study of mRNA-3705 for Methylmalonic Acidemia
August 16, 2021
From
Moderna, Inc.
Via
Business Wire
Tickers
MRNA
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.